Cargando…
Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far?
Cancers derive from step by step processes which are differentiated by the progressively accumulated mutations. For some tumors there is a clear progressive advancement from benign lesions to malignancy and for these, preventive screening programs exist. In such cases having those benign lesions are...
Autores principales: | de Melo, Fabiana Henriques Machado, Oliveira, Julia Salles, Sartorelli, Viviani Olivastro Bressani, Montor, Wagner Ricardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309127/ https://www.ncbi.nlm.nih.gov/pubmed/30627525 http://dx.doi.org/10.3389/fonc.2018.00644 |
Ejemplares similares
-
COVID-19: What We Have Learned So Far
por: Clifford, Theresa
Publicado: (2020) -
Pediatric Myocarditis: What Have We Learnt So Far?
por: Pomiato, Elettra, et al.
Publicado: (2022) -
Epigenetic signature in neural plasticity: the journey so far and journey ahead
por: Nayak, Madhusmita, et al.
Publicado: (2022) -
The hypocretins and the reward function: what have we learned so far?
por: Boutrel, Benjamin, et al.
Publicado: (2013) -
Brain Tumor Immunotherapy: What have We Learned so Far?
por: Van Gool, Stefaan Willy
Publicado: (2015)